U.S Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia) End Users- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The U.S therapeutic plasma exchange market size was estimated at USD 206 million in 2022 and is expected to hit around USD 383.07 million by 2032, poised to reach at a notable CAGR of 6.4% during the forecast period 2023 to 2032.

Key Takeaways:

• Consumables segment to witness the highest growth during the forecast period
• The centrifugation segment is expected to account for the largest share of the US therapeutic plasma exchange market in 2022
• Neurological segment to witness the highest growth during the forecast period
• On the basis of end users, the US therapeutic plasma exchange market has been segmented into blood

Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period.

U.S Therapeutic Plasma Exchange Market Report Scope

US Therapeutic Plasma Exchange Market Dynamics

Driver: Technological advancement

Continuous-flow centrifugation technology is a high-precision approach that has been refined over the past decade. It brings innovations in patient comfort and more efficient processing of blood and plasma products. This technique requires minimal blood flow compared with other technologies, such as membrane separation approaches. It is an improved technology that allows easy access to blood through the patient’s peripheral veins (antecubital or brachial), as compared with other membrane-based apheresis devices that mostly require invasive central venous catheterization. These technical innovations also result in better patient comfort and safety during the TPE procedure (than was previously possible) and more accurate fluid balance control for better hemodynamic stability during treatment. 

Restraint: High cost of devices

The cost of apheresis devices is a critical factor in determining the adoption of plasma exchange by healthcare providers and, ultimately, by patients. Apheresis devices are used by blood banks for blood component collection, while hospitals use these devices for therapeutic plasma exchange procedures. The high cost of apheresis devices and disposables also increases the overall cost of apheresis procedures. For instance, in the US, the cost of an apheresis procedure is ~USD 2,500 per treatment. Patients might not opt for these procedures owing to their high cost. 

Opportunity: Therapeutic plasma exchange for pediatric patients

The growing adoption of therapeutic plasma exchange for the treatment of various diseases is expected to offer potential growth opportunities to market players in the coming years. Therapeutic plasma exchange (TPE) is used in the treatment of neurological, hematological, renal, and autoimmune diseases with known or suspected immune pathogenesis. The use of therapeutic plasma exchange procedures in pediatric patients is very low. This therapeutic modality presents several technical challenges in children but is increasingly being used in pediatric nephrology. Owing to advances in technology, TPE procedures are carried out in pediatric patients for renal diseases. 

Challenge: Dearth of skilled professionals 

Therapeutic plasma exchange procedures require skilled professionals and apheresis nurse specialists, as most of these procedures are performed using apheresis systems. However, globally, there is a shortage of these physicians and surgeons. As the demand for TPA has increased, so has the need for apheresis nurses with their expertise in clinical patient care, transfusion medicine, and technology. Apheresis nurses provide care to a diversified population ranging from healthy donors to acute or chronically ill patients while adhering to strict, ever-changing regulatory issues. During an apheresis procedure, the nurse manages the donor/patient’s clinical status, the venous access, the infusion of blood components or specialized fluids, and the apheresis device. Additional responsibilities include donor/patient/family/public education. 

Recent Developments 

• In April 2020, Terumo BCT and Marker Therapeutics received the first device FDA emergency use authorization (EUA) to treat acute respiratory failure in COVID-19 patients.
• In May 2020, cerus corporation received FDA regulatory approval for the manufacturing of INTERCEPT plasma with a new, alternative plastic disposable kit.
• In December 2019, Haemonetics corporation opened its new corporate headquarters in Downtown Boston.
• In February 2019, Fresenius Medical Care acquired NxStage Medical to widen its product portfolio in the areas of renal care and critical care.
• In April 2020, Fresenius collaborated with DaVita and other dialysis providers to support a broader kidney care community in the US.

Some of the prominent players in the U.S Therapeutic Plasma Exchange Market include:

• Terumo BCT, Inc. (US)
• Fresenius SE & Co. KGaA (Germany)
• Haemonetics Corporation (US)
• Asahi Kasei Medical Co. Ltd. (Japan) 
• B. Braun Melsungen AG (Germany)
• Baxter International Inc. (US)
• Cerus Corporation (US)
• Kaneka Corporation (Japan)
• Kawasumi Laboratories, Inc. (Japan)
• Nikkiso Co., Ltd. (Japan)
• Miltenyi Biotec (Germany)
• Medica S.p.A. (Italy)
• Medicap Clinic GmbH (Germany)
• Infomed (Switzerland)

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S Therapeutic Plasma Exchange market.

US Therapeutic Plasma Exchange Market, By Product & Technology

• By Product
  • Consumables
  • Devices
• By Technology
  • Centrifugation
  • Membrane Separation

US Therapeutic Plasma Exchange Market, By Indication

• Neurological Disorders
  • Guillain–Barré syndrome
  • Chronic inflammatory demyelinating polyneuropathy
  • Myasthenia gravis
  • Multiple sclerosis
  • PANDASa 
• Hematology Disorders
  • Thrombotic thrombocytopenic purpura
  • Atypical haemolytic uraemic syndrome
  • Hyperviscosity syndromes
  • Severe/symptomatic Cryoglobulinemia
• Renal Disorders
  • Goodpasture’s syndrome
  • Wegener’s glomerulonephritis
  • Antibody-mediated renal transplant rejection
• Metabolic Disorders
  • Familial hypercholesterolaemia (homozygous)
• Other Indications

US Therapeutic Plasma Exchange Market, By End User

• Blood Collection Centres & Blood Component Providers
• Hospitals & Transfusion Centres
• Other End Users